Raymond James Maintains Outperform on Covetrus, Lowers Price Target to $37
Raymond James analyst Elliot Wilbur maintains Covetrus (NASDAQ:CVET) with a Outperform and lowers the price target from $38 to $37.
Covetrus Q2 GAAP EPS $(0.23) May Not Compare To $0.24 Estimate, Sales $1.19B Beat $1.11B Estimate
Covetrus (NASDAQ:CVET) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $0.24 by 195.83 percent. This is a 185.19 percent decrease over earnings of $0.27 per share from the
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
Guggenheim Upgrades Covetrus to Buy, Announces $30 Price Target
Guggenheim analyst David Westenberg upgrades Covetrus (NASDAQ:CVET) from Neutral to Buy and announces $30 price target.
Covetrus To Acquire VCP; Terms Not Disclosed
Animal health leader to combine practice, prescription, and wellness management for better veterinarian-client relationships, practice revenue and healthcare outcomes.
Covetrus® (NASDAQ:CVET), a global leader in
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell
• ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.